[Skip to Content]
[Skip to Content Landing]
October 13, 2015

Obstacles to Developing Cost-Lowering Health TechnologyThe Inventor’s Dilemma

Author Affiliations
  • 1F. Edward Hébert School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland
  • 2Departments of Medicine and Cardiology, Yale School of Medicine, New Haven, Connecticut
  • 3Yale Center for Outcomes Research and Evaluation, New Haven, Connecticut

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;314(14):1447-1448. doi:10.1001/jama.2015.10114

If a safe, inexpensive, once-a-day pill could substantially reduce the risk of myocardial infarction (MI) or stroke, would people want it? Most would probably say yes because MI and stroke are the first and third leading causes of death, respectively, in the United States.1 It is likely that many employers, health plans, and payers would also say yes because MI and stroke cost the US economy more than $300 billion annually in health care expenditures and lost productivity.2

First Page Preview View Large
First page PDF preview
First page PDF preview